Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

Podobne zapisy

• Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
  od: Cui, Shaohua, i wsp.
  Wydane: (2016)
• Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
  od: Liu, Jun, i wsp.
  Wydane: (2018)
• Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors
  od: Cui, Shaohua, i wsp.
  Wydane: (2016)
• Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
  od: Xiong, Liwen, i wsp.
  Wydane: (2017)
• ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
  od: Dacic, Sanja, i wsp.
  Wydane: (2016)